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Introduction: Diffuse cutaneous leishmaniasis (DCL) is a rare disease form associated 
with Leishmania (L.) amazonensis in South America. It represents the “anergic” pole of 
American Tegumentary Leishmaniasis, and the explanation for its resistance to treatment 
remains elusive. We aimed to study some possible immunological mechanisms involved 
in the poor DCL treatment response by evaluating some cell surface molecules obtained 
from a patient with DCL by flow cytometry.
Case presentation: A 65-year-old DCL patient who initially failed to respond to the stan-
dard treatment for the disease showed vacuolated macrophages filled with amastigotes in 
lesion biopsy, and L. (L.) amazonensis was identified through ITS1PCR amplification. The 
Leishmania skin test and indirect immunofluorescence analysis revealed negative results. 
Peripheral blood from the patient was collected after a few months of treatment, when 
the patient presented with no lesion. Peripheral blood mononuclear cells were analyzed 
ex vivo and in vitro after 48 h of stimulation with soluble L. (L.) amazonensis antigen (SLA). 
Cell death, surface molecules, and intracellular molecules, such as IFN-γ and granzyme B, 
were analyzed in the cells using flow cytometry. Analysis of the surface markers showed 
an increased expression of the inhibitory molecule programmed death ligand 1 (PD-L1) 
in the monocytes restimulated with SLA (approximately 65%), whereas the negative 
controls were 35% positive for PD-L1. Conversely, compared with the negative controls, 
we observed a decrease in CD4+IFN-γ+ T cells (8.32 versus 1.7%) and CD8+IFN-γ+ T cells 
(14% versus 1%). We also observed a relevant decrease in the granzyme B levels in the 
CD8+ T cells, from 31% in the negative controls to 5% after SLA restimulation.
Conclusion: The dysfunctional activation of PD-L1 inhibitory pathway after Leishmania 
antigen stimulation and reduced levels of IFN-gamma and granzyme B-producing cells 
could be closely related to unresponssiveness to standard drug treatment of DCL patient.
Keywords: diffuse cutaneous leishmaniasis, programmed cell death-1 ligand 1, Leishmania (L.) amazonensis, 
interferon-gamma, granzyme B, t-cell exhaustion
FIguRe 1 | Clinical presentation. (a) Erythematous plaque on the nose and 
(B) skin biopsy showing vacuolated macrophages with abundant parasites 
(HE, 400×).
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INtRoDuCtIoN
Even though Leishmaniasis is an important health problem, 
with an estimated incidence of 0.9–1.6 million each year, it is 
often overlooked during discussions of tropical diseases (1, 2). 
It is a complex zoonotic disease, with multiple animal reservoirs, 
and is primarily transmitted by the sandfly host (1). There is no 
human vaccine, and the treatment available today is based on 
toxic and poorly tolerated drugs (3, 4). The spectrum of clinical 
presentations can be divided into the following four categories: 
cutaneous leishmaniasis (CL), diffuse CL (DCL), mucocuta-
neous leishmaniasis (MCL), and visceral leishmaniasis (5). 
The form and severity of infection are related to the infecting 
Leishmania species, together with the host immune response 
(5, 6). DCL is a rare disease that affects patients showing an 
impaired cellular immune response against the parasite (7). 
Leishmania (L.) amazonensis is the primary species associated 
with this disease in South America. The disease is characterized 
by the presence of nodules, plaques, and, in some cases, ulcerated 
lesions. Histopathological examinations show an abundance 
of Leishmania-infected macrophages that fail to control the 
infection. The treatment is frequently ineffective, and patients 
are administered several toxic therapies; however, they experi-
ence poor clinical responses (7). The molecular mechanisms 
regulating the relationship between the parasite and the affected 
patient are not totally understood. DCL patients frequently show 
impairment of the Th1/cellular response; however, it is unclear 
why patients show a poor response to treatment (8).
This case report describes the flow cytometric analysis of 
the cell expression profile of surface and intracellular molecules 
from a DCL patient who presented with clinical relapse following 
standard treatment with N-methyl glucamine (NMG). The study 
aimed to identify the possible immunological mechanisms that 
lead to poor responses to DCL treatment.
Case RepoRt
A male 65-year-old resident of Brasília, Federal District, 
Brazil, presented with an erythematous plaque on his nose one 
month after fishing in the state of Amazonas, Brazil (Figure 1). 
Samples from the lesion aspirate were inoculated and cultured 
in McNeal, Novy & Nicolle medium, and smears from the 
skin biopsies were positive for Leishmania. Total DNA from 
isolated parasites in the culture was purified for molecular 
analysis using the ITS1 PCR amplification and restriction 
fragment length polymorphism (RFLP) procedures with the 
HaeIII restriction enzyme (9), which identified the species as 
L. (L.) amazonensis. The Leishmania skin test (LST) and indi-
rect immunofluorescence results were negative. Microscopic 
analysis of biopsy showed vacuolated macrophages filled with 
amastigote forms. All diagnostic procedures are described 
elsewhere (7, 10). HIV serology was negative.
The patient was initially treated with NMG (20 mg SbV/kg/day) 
for 20 days; however, no improvement was observed (11). The 
treatment was continued with the administration of 26.775  g 
that did not result in any improvement. After one month of not 
undergoing treatment, the patient resumed treatment with 20 mg 
SbV/kg/day NMG combined with allopurinol (1,200 mg/day). 
The NMG treatment was stopped after the administration of 
a 44.625  g dose due to intense myalgia. However, the patient 
resumed treatment one week later until the total dose reached 
53.55 g. We submitted this report 14 months after the admin-
istration of the first dose of NMG. The patient was still using 
allopurinol at that time. To determine the possible causes of 
this antigen-specific immune dysfunction, we performed ex 
vivo and in  vitro flow cytometric analysis of the peripheral 
blood mononuclear cells (PBMCs) of this patient. In this way, 
after the patient has undergone 11 months of treatment, being 
only administered allopurinol and presented with no lesion, we 
taBLe 1 | Surface molecule expression in ex vivo and in vitro monocytes.
surface molecules Ex vivo In vitro
Medium sLa Cona
CD14 84.9 98.3 96 59.6
CD44 99.3 99.4 99.5 97.6
HLA-DR 88.5 86.4 94.8 25.6
CD86 90.4 78.7 81.2 5.22
CD80 0.46 25.2 32.5 5.2
CD40 91.3 97.1 97.4 71.9
Programmed death ligand 1 (PD-L1) 1.19 35.5 64.9 43.2
The patient’s total peripheral blood mononuclear cells were stained with specific 
antibodies against monocyte surface molecules. Surface molecule expression was 
analyzed in a population of monocytes gated by size (FSC) and granularity (SSC).
FIguRe 2 | Cellular viability of total peripheral blood mononuclear cells (PBMCs) after SLA stimulation. The patient’s total PBMCs were stained with Annexin V and 
propidium iodide. Medium (M), soluble Leishmania amazonensis antigen (10 µg/mL SLA), and concanavalin A (15 µg/mL conA) after 48 h of in vitro restimulation.
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collected peripheral blood for immunological analysis. PBMCs 
were obtained through Ficoll gradient purification and analyzed 
ex vivo and in vitro after 48 h of stimulation with soluble L. (L.) 
amazonensis antigen (SLA). In ex vivo and in vitro experiments, 
the cells were stained with fluorochrome-conjugated anti-
bodies to analyze the surface molecules [CD14, CD40, CD44, 
CD80, programmed death ligand 1 (PD-L1), HLA-DR, CD86, 
CD3, CD4, CD8, CD45RO, CD45RA, and CD25]. For the 
in vitro experiment, positive control cells were stimulated with 
concanavalin A (conA). Cellular viability was assessed using 
Annexin V and propidium iodide (PI) labeling, acquired by 
flow cytometry (Verse/BD Biosciences, San Jose, CA, USA) and 
analyzed using FlowJo software (FlowJo, Ashland, OR, USA). 
To evaluate the production of intracellular molecules (IFN-γ 
and granzyme B), Brefeldin A was added to stop protein secre-
tion 4 h before the staining and observation by flow cytometry. 
The ex vivo (SLA unstimulated) experiments showed that the 
monocytes expressed higher percentages of CD14, CD40, CD44, 
HLA-DR, and CD86 and lower percentages of CD80 and PD-L1 
(Table 1). The in vitro experiments showed that the cells were 
viable, and no differences in the cell death markers were found 
between the SLA-treated cells and negative controls (unstimu-
lated) (Figure 2). We observed an increase in the expression of 
the inhibitory molecule PD-L1 in the monocytes restimulated 
in  vitro with SLA (approximately 65%), whereas the negative 
controls were 35% positive for PD-L1 (Figure 3). Additionally, 
8.32% of the negative control cells were CD4+IFN-γ+, but this 
percentage decreased to 1.7% after SLA stimulation. Analysis 
of the negative controls showed that 14% of the cells were 
CD8+IFN-γ+, but this percentage decreased to 1% after SLA 
restimulation. We also observed a relevant decrease in granzyme 
B expression in CD8+ T cells, from 31% in the negative controls 
to 5% after SLA restimulation (Figure 4).
DIsCussIoN
Our patient, contrary to the expected, after complete clinical 
response to treatment, more than a year after the disease onset 
and with no lesion, presented a decrease in CD4+IFN-γ+ and 
CD8+IFN-γ+ after SLA restimulation. Data from literature show 
that a classical Th1 cytokine, IFN-γ, plays diverse roles and has 
different patterns of expression, depending on the infecting 
Leishmania species. In humans, L. (L.) amazonensis antigen is a 
weaker inducer of IFN-γ production by CD4+ T cell compared 
with Leishmania (V.) braziliensis antigen in vitro (12). In contrast, 
in  vitro production of IFN-γ by PBMCs is the best indicator of 
specific immunogenicity as it has been an indicator of response to 
vaccine against dermotropic Leishmania species in humans (13). 
Nevertheless, IFN-γ plays a paradoxical role during the L. (L.) 
amazonensis infection. It favors antigen presentation and serves as 
an inducer of effector mechanisms, particularly through inducible 
nitric oxide synthase expression; however, it also induces chemokine 
expression, which leads to migration of CD4+ and macrophages 
to lesion sites, which are important in disease development (14).
These apparently contradictory findings may be explained 
by the chronology this cytokine production in the disease 
course and the Leishmania species studied. A human study in 
a L. (V.) braziliensis area showed that despite the low or absent 
IFN-γ production early in the disease, all patients with more 
than 60  days of cutaneous ulcers presented a strong antigen-
stimulated production of IFN-γ by PBMCs (15). Regarding 
the effect of treatment in IFN-γ responses by human PBMCs, 
although one study has shown a tendency for higher levels after 
treatment (16) and another showed a tendency for decreased 
production (15), more recent reports have not shown significant 
FIguRe 3 | Programmed death ligand 1 (PD-L1) expression in monocytes  
is increased after SLA restimulation. The patient’s total Peripheral blood 
mononuclear cells were stained with anti-PD-L1 antibody. PD-L1 expression 
was analyzed in a population of monocytes gated by size (FSC) and 
granularity (SSC). Medium (M), soluble Leishmania amazonensis antigen 
(10 µg/mL SLA), and concanavalin A (15 µg/mL conA) after 48 h of  
in vitro restimulation.
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differences between patients during the active disease and after 
treatment (17, 18). Together, these studies suggest that IFN-γ is 
an important molecule in the late stages of Leishmania infection 
because it is present after treatment.
Although CD8+ IFN-γ production is generaly protective in 
Leishmaniasis, it is suggested that their cytolytic activity is 
asso ciated with pathology (19). An in vitro study with PBMCs 
from patients with localized CL (LCL) and DCL has suggested 
that cytotoxicity is mediated by cytotoxic granules and that it is 
associated with granzyme B expression (20). Granzyme B seems 
to be part of the acquired Leishmania-specific immune response 
(21), and it is more highly expressed in late cutaneous lesions 
than in early ones (22). However, it is surprising that our patient 
presented with diminished granzyme B expression after SLA 
restimulation late in the disease course and with no lesions at 
that point.
We also observed that the patient PD-L1 expression on 
monocytes differed between the SLA restimulated and the 
negative control. Programmed death-1 (PD-1) is an inhibitory 
receptor that is primarily present on the surface of activated 
T cells (23), whereas its ligands (PD-L1 or PD-L2) are present 
on a variety of cell types, including antigen-presenting cells and 
many non-hematopoietic cells (24). PD-1 acts as a co-inhibitory 
receptor during the interaction of the antigenic peptide/MHC 
with the T-cell receptor (TCR) (23, 24). In addition to its role in 
self-tolerance, PD-1 is linked to pathological antigen-specific 
CD8+ and CD4+ T-cell dysfunction in chronic infections and 
parasitic diseases. This process is called cellular exhaustion 
(23, 25). Exhaustion can lead to a loss in effector function by 
affecting the IL-2, IFN-γ, and TNF-α production of T  cells, 
cytolytic activity and degranulation of CD8+ T cells (23, 26). 
Different from anergy, which is rapidly induced during the first 
encounter with the antigen, exhaustion is progressive over time 
(27), and the IFN-γ production and capacity to degranulate 
seems to be lost later, when the process is advanced (27, 28). 
In the present study, after SLA restimulation, we observed a 
decrease in IFN-γ expression by CD4+ and CD8+ and gran-
zyme B expression by CD8+. In contrast, PD-L1 expression 
increased in the presence of SLA. CD8+ T-cell exhaustion has 
been previously suggested in Diffuse Leishmaniasis caused 
by Leishmania (L.) mexicana (20). These results suggest that 
the increase in the PD-L1 expression observed in this work 
might be a mechanism that parasites exploit to avoid the 
immune response. Our findings suggest that PD-L1 expression 
by monocytes might play a role in CD8+ and CD4+ T-cell 
dysfunction in DCL. Interestingly, this T-cell dysfunction 
was observed months after the initiation of the Leishmaniasis 
treatment, despite the increase of costimulatory molecules 
after SLA stimulation, and it resulted in low IFN-γ in CD8+ 
and CD4+ and granzyme B on CD8+. Together it is possible to 
assume that, as a consequence of the chronic exposition to the 
Leishmania antigen, this patient presented with T-cell exhaus-
tion that persisted despite clinical cure. This is in accordance 
with the concept that exhaustion takes between 2 and 5 weeks 
to develop and affects both cytotoxic and helper functions, and 
exhausted cells do not recover their functions even after the 
removal of the antigen (28, 29).
Our patient showed a higher percentage of CD8 T  cells 
than CD4 T in the unstimulated condition. One possibility 
is that the treatment was sufficient, by this time of immuno-
logical evaluation, to restore the CD8 T cells numbers and not 
5Barroso et al. T-Cell Exhaustion in Diffuse Leishmaniasis
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FIguRe 4 | SLA decreased IFN-γ production by CD4+ cells and IFN-γ/granzyme B production by CD8+ T cells. The patient’s total peripheral blood mononuclear 
cells were stained with anti-CD4, anti-CD8, anti-IFN-γ and anti-granzyme B antibodies. (a) Lymphocytes were gated by size (FSC) and granularity (SSC), and  
IFN-γ was analyzed in a CD4+ population. (B) IFN-γ or granzyme B expression was analyzed in a CD8+ population. Medium (M), soluble L. amazonensis  
antigen (10 µg/mL SLA), and concanavalin A (15 µg/mL conA) after 48 h of in vitro restimulation.
CD4 T  cells. This observation can suggest a different role of 
CD8 T  lymphocytes in our DCL patient. In fact, data from 
literature show that the number of CD4 and CD8 lymphocytes 
from DCL patients peripheral blood can ne altered during 
the healing process, increasing 86.5 and 37%, respectively 
and normalizing the CD4/CD8 ratio. In a moment prior to 
treatment, the CD8 T cells from DCL patients were found dif-
fusely distributed by the inflammatory tissue, whereas after the 
treatment, a higher number of CD8 T lymphocytes was found 
localized in the inflammatory infiltrate. However, 5  months 
after the end of the treatment, CD8 T  cells decreased to 
abnormal numbers in the peripheral blood (30). We observed 
a decrease of IFN-γ and granzyme B in SLA stimulated CD8+ 
cells. The viable CD8 T  cells from lesion of DCL patients 
caused by L. mexicana showed a decrease in cytotoxicity, 
antigen-specific proliferation and IFN-γ production after co-
cultured with macrophages infected with this parasite. This 
anergic response by CD8 T  cells was restored after stimuli 
by two TLR2 antagonists (LPG and Pam3Cys). Also, PD-1 
expression on CD8 T cells was decreased after the stimuli (20). 
All these results suggest that the low presence of CD4 cells and, 
mainly, the anergic CD8 cells can be contributing to unrespon-
sitivity to treatment and probably, to the persistence of DCL.
Diffuse CL is associated with difficult therapeutic manage-
ment and is often a chronic infection (31). PD-1 blockade using 
monoclonal antibodies is currently under investigation for the 
treatment of other chronic infectious diseases and has shown 
promising results (32). Thus, studying this receptor in DCL is 
a relevant step toward the development of better therapeutic 
strategies. The patient showed good clinical results after com-
bination treatment with NMG and allopurinol. Early diagnosis 
and treatment are crucial for achieving a satisfactory clinical 
outcome. As shown by our results, despite treatment and a 
patient without lesions at the time of immunological evaluation, 
a selective exhausted state can persist after Leishmania antigen 
stimulation and this state is possibly caused by the induction 
of the PD-L1 inhibitory pathway, once we observed a higher 
expression of PDL-1 in monocytes.
The increase in PD-L1 expression was also observed through 
recognition of polyI:C by TLR3 in a CD40/CD40L interac-
tion and NFkB-dependent manner (33). Although TLR3 is 
a receptor that recognizes double-stranded RNA (dsRNA), 
many studies have identified the presence of Leishmania 
RNA virus (LVR) in several Leishmania species, such as L. 
(V.) braziliensis, Leishmania (V.) guyanensis, Leishmania 
(L.) aethiopica, Leishmania (L.) major, and Leishmania (L.) 
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infantum (33–37). Murine studies have found an increase in 
cytokine and chemokine production, susceptibility to para sites, 
footpad swelling and parasitemia after Leishmania infection 
and recognition by TLR3 (38). Moreover, the presence of the 
LVR in Leishmania has been associated with non-response to 
treatment. In a recent cohort of 76 American Tegumentary 
Leishmaniasis patients, subjects infected with L. (V.) guyan-
ensis that carried LVR did not respond to treatment, while 
subjects with Leishmania without the RNA virus did respond 
to treatment (36). Treatment failure was also observed dur-
ing L. (V.) braziliensis with LVR infection (37). A study 
performed in the state of Rôndonia found an association of 
mucosal Leishmaniasis and the presence of the RNA virus in 
Leishmania species (39). In the same study, LVR was found in 
L. (L.) amazonensis isolated from two patients (39). Although 
the state of Minas Gerais has a low incidence of LVR in L. (V.) 
braziliensis, most prospective studies that identified the pres-
ence of LVR1 are from the Amazonian region (40). In this way, 
it is worth on note that our patient reported having been in 
the state of Amazonas before the onset of the lesions. In vitro 
experiments showed an increase in PD-L1 expression and the 
exhaustion of CD4+ and CD8+ T cells after SLA stimulation. 
Thus, we suggest that LVR is present in L. (L.) amazonensis and 
recognized by TLR3, which would trigger the increase in PD-L1 
expression, leading to the exhaustion of T cells, as evidenced 
by the decrease in the expression of IFN-γ and granzyme B.
Based in our in  vitro experiments results, we suggest that 
PD-L1 inhibitory pathway may be related to unresponsiveness to 
standard drug treatment of DCL patient.
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